- View All Journals
- Expert Opinion on
- Expert Review of
- Anticancer Therapy
- Anti-infective Therapy
- Cardiovascular Therapy
- Clinical Immunology
- Clinical Pharmacology
- Endocrinology & Metabolism
- Gastroenterology & Hepatology
- Medical Devices
- Molecular Diagnostics
- Obstetrics & Gynecology
- Pharmacoeconomics & Outcomes Research
- Respiratory Medicine
- Current Medical Research and Opinion
- Journal of Medical Economics
- Journal of Drug Assessment
- View All Books
- View Book Series
- Basic and Clinical Dermatology
- BioMed Tracker Reports
- Clinical and Basic Science Dermatology
- Cosmetic Science and Technology
- Drugs and the Pharmaceutical Sciences
- European Society of Medical Oncology
- Fundamental and Clinical Cardiology
- Infectious Disease and Therapy
- Lung Biology in Health and Disease
- Medical Psychiatry
- Reproductive Medicine/Assisted Tech
- Series in Cosmetic and Laser Therapy
- Series in Dermatological Treatment
- Series in Maternal-fetal Medicine
- Target Organ Toxicology
- Translational Medicine
- Encyclopedias and Reference Works
- Expert Opinion on Cardiovascular Disease
- Expert Opinion on Haematology
- Expert Opinion on Infection
- Expert Opinion on Musculoskeletal Disorders
- Expert Opinion on Neurology
- Expert Opinion on Oncology
- Expert Opinion on Psychiatry
- Expert Opinion on Respiratory Disease
- Informa Healthcare Diabetes Collection
Expert Opinion on Drug Metabolism & Toxicology
About the Journal
- The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Theodosios D Filippatos,
Vasilios G Athyros,
Moses S Elisaf
- Drug-induced liver injury: what was new in 2013?
Walid M Chalhoub,
Kayla D Sliman,
James H Lewis
- Sources of preanalytical error in pharmacokinetic analyses – focus on intravenous drug administration and collection of blood samples
Alan V Boddy,
- Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder
Massimo Carlo Mauri,
Alfredo Carlo Altamura
- Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions
April 22, 2022Journals across the Expert Collection have considered injurious therapeutics to fertility; offering a wealth of information for those prescribing and taking potentially toxic xenobiotics.
April 9, 2022The editor’s pick form Dr Luis Valerio for the April issue of Expert Opinion on Drug Metabolism & Toxicology is a review paper by Dr Himebauch and Dr Zuppa of Philadelphia, entitled ‘Methods for pharmacokinetic analysis in young children’.
April 7, 2022Welcome to this month’s Toxicology and Drug Metabolism newsletter.
Below you will find the latest published articles across all of Informa Healthcare’s Toxicology and Drug Metabolism journals.
Editor-in-Chief picks review investigating the impact of inter-individual genetic difference on antiepileptic drugsFebruary 26, 2022The editor’s pick from Dr Luis Valerio for the March issue of Expert Opinion on Drug Metabolism & Toxicology is a review article by Professor Oscar Della Pasqua and colleagues. Their review entitled ‘Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs’ explores the inter-individual genetic differences that can lead to altered pharmacokinetics and pharmacodynamics of antiepileptic drugs.
February 4, 2022The Editor’s pick from Dr Luis Valerio (Silver Spring, MD, USA) for the February issue of Expert Opinion on Drug Metabolism & Toxicology is ‘Exploring concepts of in vitro time-dependent CYP inhibition assays’. This article comes from David M Stresser et al. (Corning Life Sciences, USA) and you can read more here.
January 8, 2022The Editor’s pick from Dr Luis Valerio (Silver Spring, MD, USA) for the January issue of Expert Opinion on Drug Metabolism & Toxicology is ‘The effects of acute renal failure on drug metabolism’. This article comes from Philips et al. (St. George’s, University of London, UK), click the link above to read more…
December 20, 2013Want to learn more about some of the in vitro methods being used to discover and develop drugs? Both Expert Opinion on Drug Discovery and Expert Opinion on Drug Metabolism & Toxicology have been examining just that – click above to find out more.
December 18, 2013The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
Editor’s Pick for December – reviewing the preclinical ADME data of FDA-approved small molecule kinase inhibitorsDecember 4, 2013The Editor’s pick from Dr Luis Valerio (Silver Spring, MD, USA) for the December issue of Expert Opinion on Drug Metabolism & Toxicology is ‘Small molecule kinase inhibitors aproved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data’. This article comes from O’Brien et al. (Celgene Corp., USA), click the link above to read more…
November 6, 2013The Editor’s pick from Dr Luis Valerio (Silver Spring, MD, USA) for the November issue of Expert Opinion on Drug Metabolism and Toxicology is ‘The current status of biomarkers for predicting toxicity’. This article comes from Sarah Campion et al. (Pfizer, Inc., USA), click the link above to read more…
November 5, 2013Welcome to the November issue of the Toxicology and Drug Metabolism newsletter.
This month, we are pleased to offer you FREE access to 3 of the top downloaded articles from our Toxicology and Drug Metabolism journals
October 22, 2013This Week in the Expert Opinion journals, we look into new and not-so-new therapies for cancer, the pharmacokinetics of a common contraceptive, and wonder what special considerations are needed for clinical trials of orphan drugs. Find out more here…
October 4, 2013Our editor in chief has chosen the article entitled “Streptomyces cytochromes P450: applications in drug metabolism” by David C Lamb, Michael R Waterman and Bin Zhao as the Editor’s pick for the October edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
September 13, 2013Drug absorption, distribution, metabolism and excretion considerations in critically ill adults by Derek J Roberts and Richard I Hall
August 16, 2013The FDA defines a First-in-Class drug as one which uses a new and unique mechanism of action for treating a medical condition. This is a concept that immediately makes you think of words like ‘innovation’, ‘novelty’, ‘potential’, ‘pioneering’ and ‘cutting-edge’ – all things that most pharmaceutical companies look for when considering areas of R&D to pursue and invest in. While they have the potential to boost the company’s pipeline and its profit, First-in-Class drugs also come with much greater risk and are definitely not guaranteed to succeed.
July 29, 2013Following the editorial highlight last week, we are happy to announce the Editor’s Pick for the recently published August issue of Expert Opinion on Drug Metabolism and Toxicology. This month’s selection is a review article on the “toxicty of topical ophthalmic anesthetics” written by M Patel and FW Fraunfelder.
Editorial Highlight: Depression in the elderly – what are the pharmacogenetic considerations? (August 2013)July 23, 2013The treatment of depression is, at the best of time, a complicated process that often relies on a number of different drugs being tested before the correct treatment is received. However, first-line therapy for depression has been shown to have a lower therapeutic outcome in the elderly.
Editorial Office News: New Original Research Article co-authored by our Editor in Chief, Luis Valerio Jr.July 18, 2013The editorial office is delighted to announce the publication of the Original Research Article “Development of cardiac safety translational tools for QT prolongation and torsade de pointes” in Expert Opinion on Drug Metabolism and Toxicology. Amongst the authors of this article is our Editor in Chief, Luis Valerio Jr.
July 9, 2013Welcome to the July issue of the Toxicology and Drug Metabolism newsletter.
This month, we are pleased to offer you FREE access to 3 of the top downloaded articles from our Toxicology and Drug Metabolism journals
July 1, 2013Our editor in chief has chosen the article entitled “Microdosing and drug development: past, present and future” by Lappin G et al. as the Editor’s pick for the July edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
June 14, 2013Welcome to the June issue of the Toxicology and Drug Metabolism newsletter.
As part of our continued support and collaboration with you, we are pleased to offer you FREE access to these articles from our Toxicology and Drug Metabolism journals
June 3, 2013Our editor in chief has chosen the article entitled “Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations” by Bloomer et al as the Editor’s pick for the June edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
May 13, 2013Toxicology and Drug Metabolism Newsletter_May
April 29, 2013Our editor in chief has chosen the article entitled ” Cytochrome P450-mediated metabolism in brain: functional roles and their implications” by Ravindranath V and Strobel HW as the Editor’s pick for the May edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
April 12, 2013Our editor in chief has chosen the article entitled “Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.” by H Barton, Y Lai, H Jones et al. as the Editor’s pick for the April edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
April 11, 2013Our editor in chief has chosen the article entitled “Species differences in drug transporters and implications for translating preclinical findings to humans” by X Chu, K Bleasby and R Evers as the Editor’s pick for the March edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
Recent Publications on the Fixed Combination of Linagliptin + Metformin for the Treatment of Type II DiabetesMarch 14, 2013We have recently published two highly viewed drug evaluations on the fixed-combination drug of linagliptin and metformin (also known as Jentadueto®).
January 11, 2013
Our editor in chief has chosen the article entitled “GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations” by MJ Jespersen, FK Knop and M Christensen to be the first Editor’s pick for the January edition of the 2013 volume of Expert Opinion on Drug Metabolism and Toxicology.
December 10, 2012
This issue of the journal features an article on how in silico models for genotoxicity prediction have been evaluated including performance metrics.
Latest advances in computational genotoxicity prediction by Russell Naven, Nigel Greene, Richard Williams is our Editor’s pick for December 2012.
October 26, 2012
Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain (Niesters M and Dahan A)
Our Editor’s pick for November Our Editor’s pick for November discusses the efficacy of subanesthetic doses of ketamine in alleviating chronic neuropathic pain, and highlights its pharmacokinetics and dynamics.
August 22, 2012
Current regulatory approaches of bioequivalence testing (Karalis and Macheras)
Our Editor’s pick for August reviews the current regulatory procedures on bioequivalence testing. Special focus is placed on the guidelines recommended by the European Medicines Agency and the US Food and Drug administration. The authors also describe the evolution of these issues and the alternatives proposed in the literature.
May 11, 2012
Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants (Koturbash, Beland and Pogribny)
Our Editor’s pick for May provides summarizes the current knowledge of the role of miRNAs in the regulation of drug (xenobiotic) metabolizing genes and the cellular responses to exposure to exogenous toxicants.
March 30, 2012
In vitro-to-in vivo predictions of drug–drug interactions involving multiple reversible inhibitors (Lutz and Isoherranen)
Our Editor’s pick for April provides an overview of the reliability of the in vitro determined reversible inhibition mechanism. Furthermore, the article provides a method to predict DDIs for multiple reversible inhibitors.
March 27, 2012In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
March 16, 2012
Free access to the March edition of Informa Healthcare’s Toxicology and Drug Metabolism Newsletter
March 7, 2012
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions – (JD Clarke and NJ Cherrington)
Our Editor’s pick for March discusses the role that Organic anion transporting polypeptides (OATP) play in adverse drug reactions, considered in the context of genetic or environmental factors.
February 21, 2012
Free access to February edition of Informa Healthcare’s Toxicology and Drug Metabolism Newsletter.
February 16, 2012
Standardization of pluripotent stem cell cultures for toxicity testing
Pluripotent stem cell (PSC) lines offer a unique opportunity to derive various human cell types that can be exploited for human safety assessments in vitro and as such contribute to modern mechanistically oriented toxicity testing.
January 16, 2012FREE access to Informa Healthcare’s Toxicology and Drug Metabolism Newsletter – January 2012
January 10, 2012
Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation
Reliable in vitro and in silico assays as alternatives for in vivo developmental toxicity studies are urgently needed, for the replacement, reduction and refinement (3Rs) of animal use in toxicological research. Therefore, relevant biomarkers for in vivo developmental toxicity in in vitro assays are needed.
December 13, 2011
FREE ACCESS to the December edition of Informa Healthcare’s Toxicology and Drug Metabolism eNewsletter: http://bit.ly/rTcG0U
Introducing Dr Luis Valerio Jr as the new Editor in Chief of Expert Opinion on Drug Metabolism and ToxicologyNovember 2, 2011We are delighted to announce that Dr Luis Valerio Jr of the Center for Drug Evaluation and Research, FDA, has accepted our invitation to become the first Editor in Chief of Expert Opinion on Drug Metabolism and Toxicology.